Evidence map›Paper›PMID 41810956›Full record

ArticleMicrobiology spectrum2026

A visible assay for evaluating the inhibitory activity of drug and antibody against HBV infection.

Hu Yan, Yuxiao Li, Congcong Liu, Huimin Guo, Yufeng Liu, Haiyan Wang, Xiangyang Ge, Zheng Zhang, Bin Ju

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hu Yan *Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China.
Yuxiao Li *Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China.
Congcong LiuInstitute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China.
Huimin GuoInstitute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China.
Yufeng LiuInstitute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China.
Haiyan WangInstitute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China.
Xiangyang GeInstitute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China.
Zheng ZhangInstitute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China.ORCID 0000-0002-3544-1389
Bin JuInstitute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China.ORCID 0000-0003-0768-6327

Funding

National Natural Science Foundation of China 82025022National Natural Science Foundation of China 82171752, 82322040
6 · The paper itself

Abstract

Viral infectivity detection assays play an important role in the quantitative titers of virus and the effect of drugs and antibodies against virus infection. However, detecting the infectivity of hepatitis B virus (HBV) via conventional plaque assays still poses challenges because its infection does not result in cytopathic effects and progeny viruses struggle to infect adjacent cells IMPORTANCE: In this study, we report a sensitive and reliable immunospot assay for the visible quantitative detection of HBV infection. This assay demonstrates excellent performance in evaluating the inhibitory effect of antiviral drugs, neutralizing antibodies, and plasma samples from vaccinated individuals. Given its robustness and versatility, the proposed method is anticipated to be an excellent alternative assay for HBV-related research, including therapeutic development and vaccine evaluation.

Indexed as

Antiviral AgentsHepatitis BHepatitis B AntibodiesHepatitis B virusAntibodies, MonoclonalAntibodies, NeutralizingHumansSensitivity and SpecificityAntibodies, MonoclonalAntibodies, NeutralizingAntiviral AgentsHepatitis B Antibodieshepatitis B virusquantitative detectionvisible immunospot assay

Identifiers

PMID41810956
PMCPMC13055246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.